title: The pharmacological profile of mouse hind paw inflammation induced by staphylococcal enterotoxin type A.
abstract: OBJECTIVE
  The present paper examines the possible pharmacological mediators involved in mouse hind paw inflammation induced by staphylococcal enterotoxin type A (SEA).
  
  
  METHODS
  The edema and the Evans blue exudation were measured in male Swiss mice (20-25 g) using methods described by Levy and Griswold, respectively.
  
  
  RESULTS
  SEA (32 micrograms/paw) produced a biphasic, long-lasting, dose- and time-dependent edematogenic response. The acute phase edema was pronounced while the chronic edema was of a low intensity. Exudate was the principal component of the edema. The edematogenic effect of SEA appears to involve cyclooxygenase products and was dose-dependently reduced by pretreating the mice with dexamethasone, indomethacin, BW755C, WEB2086, capsaicin, diphenhydramine or cimetidine.
  
  
  CONCLUSIONS
  These results demonstrate that SEA-induced mouse hind paw inflammation is a useful model for studying SEA-mediated enterotoxemia and may be sufficiently sensitive to differentiate between the effects of SEA and those of SE type B (SEB).
authors.affiliation: Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, Cidade Universitária, Zeferino Vaz, Brazil.
authors.forename: I A
authors.initials: IA
authors.lastname: Desouza
authors.forename: G
authors.initials: G
authors.lastname: Ribeiro-DaSilva
mesh_terms: D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine / Q000627:therapeutic use; D000818:Animals; D001381:Azepines / Q000627:therapeutic use; D002211:Capsaicin / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004155:Diphenhydramine / Q000627:therapeutic use; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D004768:Enterotoxins; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006614:Hindlimb; D006633:Histamine Antagonists / Q000494:pharmacology; D007213:Indomethacin / Q000627:therapeutic use; D007249:Inflammation / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D051379:Mice; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D001381:Azepines; D004768:Enterotoxins; D004791:Enzyme Inhibitors; D006633:Histamine Antagonists; D010975:Platelet Aggregation Inhibitors; D014230:Triazoles; C052518:WEB 2086; C026066:enterotoxin A, Staphylococcal; D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; D003907:Dexamethasone; D002927:Cimetidine; D004155:Diphenhydramine; D002211:Capsaicin; D007213:Indomethacin